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A B S T R A C T
Aims: Neuroendocrine tumors (NET) of the cervix are rare tumors with a very aggressive course. The human
papillomavirus (HPV) has been linked to its etiology. The objective of this study is to describe HPV prevalence
and genotype distribution of NET.
Methods and Results: Forty-nine tumors with histological neuroendocrine features were identified among 10,575
invasive cervical cancer (ICC) cases from an international study. HPV DNA detection was done using SPF10/
DEIA /LiPA25 system. Immunohistochemical (IHC) staining for neuroendocrine markers (chromogranin A, sy-
naptophysin, CD56) and for p16INK4a as a surrogate for HPV transforming infection was performed. In 13
samples with negative IHC for all 3 neuroendocrine markers studied, it was possible to conduct electron mi-
croscopy (EM).
NET represented 0.5% of the total ICC series and HPV was detected in 42 out of 49 samples (85.7%,
95%CI:72.8%,94.1%). HPV16 was the predominant type (54.8%), followed by HPV18 (40.5%). p16INK4a over-
expression was observed in 38/44 cases (86.4%). Neuroendocrine IHC markers could be demonstrated in 24/37
(64.9%) cases. EM identified neuroendocrine granules in 8 samples with negative IHC markers.
Conclusions: Our data confirms the association of cervical NET with HPV and p16INK4a overexpression.
Specifically, HPV16 and 18 accounted together for over 95% of the HPV positive cases. Current HPV vaccines
could largely prevent these aggressive tumors.
1. Introduction
Neuroendocrine tumors (NET) of the cervix are rare, accounting for
0.5–1% of all cervical carcinomas [1]. Since 1972, when the first study
of carcinoid tumor of the cervix was published by Albores-Saavedra
[2,3], some small series have been reported. Currently, the World
Health Organization (WHO) includes 4 types of NET: carcinoid (C),
atypical carcinoid (AC), small cell carcinoma (SmCC) and large cell
neuroendocrine carcinoma (LCC) [1]. However, terminology to cate-
gorize cervical NET has not always been clear [4] and diagnostic cri-
teria are not very well defined, particularly large cell carcinomas [1]
can be difficult to distinguish from poorly differentiated squamous
carcinomas or adenocarcinomas. Neuroendocrine carcinoma of the
cervix has a poor prognosis, with a high tendency to relapse and its
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precise diagnosis is of clinical relevance [5,6]. This is related to the fact
that 90% of the cases present lymph-vascular invasion which is poor
prognosis finding in most malignant tumors. Therefore, comparative
studies of frequency, histological features, clinical behavior and the
natural history of this group of tumors are limited.
The association between squamous cell carcinoma (SCC), adeno-
carcinoma (ADC) or adenosquamous carcinoma (ADSCC) of the cervix
with human papillomavirus (HPV) has been well established and
documented [7–9]. Overexpression of p16INK4a, a cyclin dependent ki-
nase inhibitor, is associated with high risk HPV due to E7 mediated
inactivation of retinoblastoma tumor suppressor, and a negative feed-
back loop. p16INK4a immunohistochemistry shows positive staining in
nearly all squamous cell carcinomas (97%) and in about half of ade-
nocarcinomas (48–50%) [10,11]. The expression of this protein,
p16INK4a, in NET of the uterine cervix is not well established.
According to published data, HPV detection in NET tumors ranged
between 0 and 100%, with HPV18 and 16 being the most frequently
detected genotypes [5,12–28]. The use of techniques with different
sensitivity to detect HPV DNA, the inclusion criteria of the samples in
each study and total cases included, and different methods of tissue
conservation in the different participant centers may be the explanation
for this wide range of results among series.
We present HPV DNA detection and genotype distribution, together
with the histological and immunohistochemical features in 49 NET of
the cervix.
2. Materials and Methods
2.1. Study design and materials
The Catalan Institute of Oncology (ICO) in Barcelona, Spain and the
DDL Laboratories in Rijswijk, The Netherlands, have conducted an in-
ternational study on HPV DNA detection in invasive cervical cancer
(ICC) cases as previously described [8]. This study included 10,575 ICC
cases from pathology archives from 38 countries of 5 continents diag-
nosed from 1940 to 2009. Participant centers provided consecutive
cases diagnosed as ICC with basic information (country, histological
diagnosis, age at diagnosis and year of diagnosis). After reviewing the
histological diagnosis for these 10,575 cases by a team of 3 pathologists
from ICO, 54 NET were identified. Five cases were excluded from the
present study since the diagnosis was performed at the center of origin
and not confirmed at ICO (unavailable Haematoxylin and Eosin-HE
slide), leaving 49 NET cases confirmed by the ICO panel of pathologists
using the criteria described by Albores-Saavedra et al. [3]. An algorithm
of the study and procedures performed is shown in Fig. S1 of the sup-
plementary material.
2.2. Tissue processing and histological diagnosis
Tissue processing and pathology diagnosis were done by the re-
ference pathology laboratory at ICO. Paraffin blocks were processed
under strict conditions to prevent contamination. First and last sections
were used for histopathological evaluation on HE slides while inter-
mediate sections were used for HPV DNA detection and genotyping. In
addition, a blank paraffin section was cut between specimens to prevent
any carry over contamination. Pathology evaluation was done from an
HE slide of one tissue block and included: confirmation of ICC, histo-
logical classification, quantitation of tumor necrosis, amount of in-
vasive tumor in the tissue section and presence of normal mucosa and/
or preneoplastic lesion.
WHO classification of NET of the uterine cervix was used to sub-
categorize the cases as C-Carcinoid, AC-Atypical carcinoid, LCC-Large
cell neuroendocrine carcinoma, SmCC-Small cell carcinoma, categories.
SmCC and LCC carcinomas were distinguished from C and AC taking
into account architectural and cytological features. Infiltrative margins,
high mitotic rate (> 10/10 high power fields) and extensive geographic
areas of necrosis ruled out C and AC. Small cells with scant cytoplasm
and the presence of compacting artifact were criteria to diagnose SmCC.
LCC was diagnosed on the basis of chromatin features and larger cy-
toplasm compared to SmCC.
2.3. HPV testing
For each specimen, a paraffin tissue section was treated with 250 µl
of freshly prepared Proteinase K solution to extract DNA. SPF-10
polymerase chain reaction (PCR) was performed using 10 µl of the DNA
extract with a 1:10 dilution in a final reaction volume of 50 µl. The
amplified PCR products were tested using a probe hybridization step
with a cocktail of conservative probes, recognizing at least 54 mucosal
HPV genotypes, in a microtiter plate format for the detection of HPV
DNA through DNA Enzyme Immunoassay (DEIA). Optical densities
(OD450) were read on a microtiter plate reader and categorized as HPV
DNA negative, positive, or borderline. After PCR, 10 µl of the amplimers
DEIA HPV DNA positive were used to perform the reverse hybridization
line probe assay (LiPA25) (version 1: produced at Laboratory
Biomedical Products, Rijswijk, The Netherlands) [29]. LiPA25 detects
25 high-risk (HR) and low risk (LR) HPV types (6, 11, 16, 18, 31, 33, 34,
35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, and
74). The sequence variation within the SPF-10 primers allows the re-
cognition of these different HPV genotypes, except for types 68 and 73,
as their inter-primer regions are identical and cannot be distinguished
by this test. Positive hybridization on the strips is visualized as a purple
band by means of a precipitating color substrate on the probe site.
2.4. Immunohistochemistry
Immunohistochemical (IHC) staining was performed with the au-
tomated system Autostainer Link 48 (Dako Co, Carpinteria, CA) using
primary antibodies to chromogranin (clone DAK-A3 DAKO), synapto-
physin (clone 5438 DAKO) and CD56 (clone 123c DAKO), following the
manufacturer's recommendations. Immunohistochemical neuroendo-
crine differentiation was considered when at least one of the three
markers depicted cytoplasmic or membrane positive staining in tumor
cells, even if it was focally.
As a surrogate of a transforming high risk HPV infection p16INK4a
was detected using the CINtec histology kit (clone E6H4, mtm
Laboratories, Heidelberg, Germany), following the manufacturers pro-
tocol. A pattern of diffuse nuclear and cytoplasmic staining (> 50%)
was considered a positive result.
In each run a negative and a positive control were included. These
markers were performed when there was available material. Details on
available material by marker are shown in Fig. S1 of the supplementary
material.
2.5. Electron microscopy
Electron microscopy (EM) was performed in 16 cases, 13 cases with
negative IHC for all the neuroendocrine markers performed, and 3 with
IHC positive results used as controls. Appropriate areas were selected
from original paraffin blocks and sampled with a tissue microarray
needle (1 mm in diameter), deparaffined, post fixed in osmium tetr-
oxide and embedded in epoxy resin. Sections were examined with a
Phillips (FEI) CM 100 transmission electron microscope. The presence
or absence of cell junctions and neuroendocrine granules in well pre-
served samples was reported.
2.6. Statistical analysis
Data analysis was performed with STATA version 10.0 (Stata
Corporation, Computing Resource Center, College Station, Texas).
A descriptive analysis was performed by calculating proportions and
95% Confidence Interval-95%CI for qualitative variables and central
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tendency and variability measures for quantitative variables. One-way
ANOVA was used for comparison of age at diagnosis by histology, and
Chi-Squared test for comparing HPV positivity by histological major
groups. We assessed levels of similarity concordance between the HPV
test and p16INK4a by Kappa score. McNemar chi-squared test for mat-
ched pair data was used for assessing unequal distribution of discordant
results. Significance for all analyses was set at the 2-sided 0.05 level.
HPV positivity refers to the percent positive cases among all HPV
analyzed cases. HPV type-specific relative contribution refers to the
percent positive for a given type, related to all HPV positive samples.
Multiple-infected cases were counted as follows: 1) As one case (com-
bination of types) in Table 2; 2) Adding multiple infections to single
types under a proportional weighting attribution in Fig. 2 [8], and 3)
Counting infections not cases, this is each HPV type as one infection
either in single and multiple infections in Table 3.
2.7. Ethical issues
All protocols were approved by local and ICO ethics committees and




Among 10,575 cervical carcinomas, 49 NETs were identified from
histology, representing 0.5% of the total series. Table 1 describes the
distribution of the cases by region and time of diagnosis. We com-
paratively observed no significant differences either within or between
NET and various other tumors types, which were compared, con-
sidering different regions and times of diagnosis. The mean age at di-
agnosis of NET was 51.8 years (Standard Deviation: 15.0 years).
In accordance with the WHO classification of NET cases were sub-
categorized as C (N=1), AC (N=4), LCC (N=11) and SmCC (N=33)
(Fig. S1 of supplementary material). In 7 cases there was a second
component identified: 5 carcinomas contained areas of ADC, one
showed SCC, and another undifferentiated carcinoma.
3.2. HPV Analysis
HPV DNA was detected in 85.7% (95%CI: 72.8%, 94.1%) of NET
(42/49), in concordance with results of the whole ICC series (84.2%,
95%CI: 84.2%, 85.6%; p-value> 0.05) [8]. 97.6% of the HPV positive
cases were infected only with one HPV type (single infection) and one
SmCC case was infected by 2 HPV types (HPV18&HPV52) (Table 2).
Fifty five percent of NET cases were HPV16 positive; 41% were positive
for HPV18 and 4% were positive for other types (Fig. 2). The genotype
distribution by histology showed a statistically significant higher pro-
portion of HPV18 in NET cases compared to SCC and other histologies.
3.3. Immunohistochemistry for NET differentiation
All three immunohistochemical markers (chromogranin, CD56 and
synaptophysin) could be performed in 37 out of 49 cases (Fig. 3 and
Table 2) and 64.8% were positive for at least one marker. No tissue
Fig. 1. Images of Hematoxylin & Eosin staining and p16INK4a in neuroendocrine tumors. - (a) Small cell carcinoma. Low power of small cell carcinoma with a nesting
pattern; (b) Small cell carcinoma; (c) Atypical carcinoid; (d) Large cell neuroendocrine carcinoma; (e) Neuroendocrine tumor with strong intracytoplasmatic and
intranuclear staining with p16INK4a.
Fig. 2. HPV type distribution among HPV positive cases by histological clas-
sification. “ICC”-Invasive Cervical Cancer; “SCC”-Squamous Cell Carcinoma;
“ADC”-Adenocarcinoma; “ADSCC”-Adenosquamous Cell Carcinoma; “OTHER”-
Mostly undifferentiated cases; “NET”-Neuroendocrine Tumors. (*) Other cate-
gory, does not contain NET cases.
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from the carcinoid NET was available on which to perform IHC NET
markers. Three AC displayed positive staining for all 3 markers, LCC
showed at least one positive marker in 7 cases (70.0%) and 3 cases were
completely negative. Among SmCC, 10/24 (41.7%) were positive for at
least one IHC NET marker. When analyzed individually each marker,
CD56 was the most frequently positive immunohistochemical marker
61.5% (24/39) followed by chromogranin 38.5% (15/39) and sy-
naptophysin was detected in 25.6% (10/39) of the cases.
3.4. Electron microscopy (EM)
Three out of 13 cases showed poor preservation and were con-
sidered inadequate for EM interpretation. Primitive cell junctions were
found in 6 cases and 5 showed desmosomes. Neurosecretory-type
granules, with diameters ranging from 60 to 339 nm, were seen in 8
cases (Fig. 3). Overall, EM confirmed neuroendocrine differentiation in
8 (2 LCC and 6 SmCC) out of 10 cases that were IHC negative for all
available markers (Table 2). All positive controls showed neurosecre-
tory granules.
3.5. p16INK4a inmunohistochemistry
p16INK4a staining could be performed in 44 cases and 86.4%
(95%CI: 72.6%,94.8%) showed over-expression (Table 2). All C, AC and
LCC were p16INK4a positive (Fig. 1), while 22 of 28 (78.5%) SmCC
showed p16INK4a positive staining. All p16INK4a negative cases showed
poor tissue preservation. Overall, concordant results of p16INK4a and
HPV detection was observed in 88.6% of the cases (Kappa Index: 0.549,
p-value<0.001, McNemmar test p-value>0.05).
Table 1
Number of invasive cervical cancer cases included for HPV DNA detection in the entire series [8] by region and time at diagnosis, stratified by histological categories.
ICC cases HPV analyzed SCC ADC ADSCC OTHER NET (*)
N N (%) N (%) N (%) N (%) N (%)
Region
Europe 2,364 2,093 (88.5) 209 (8.8) 43 (1.8) 12 (0.5) 7 (0.3)
North America 176 160 (90.9) 13 (7.4) 0 (0.0) 2 (1.1) 1 (0.6)
Latin America 4,171 3,764 (90.2) 261 (6.3) 80 (1.9) 45 (1.1) 21 (0.5)
Africa 691 609 (88.1) 58 (8.4) 17 (2.5) 4 (0.6) 3 (0.4)
Asia 2,994 2,722 (90.9) 197 (6.6) 39 (1.3) 19 (0.6) 17 (0.6)
Oceania 179 138 (77.1) 22 (12.3) 12 (6.7) 2 (0.8) 0 (0.0)
Time at diagnosis
1940–1949 114 99 (86.8) 11 (9.6) 2 (1.8) 1 (0.9) 1 (0.9)
1950–1959 533 483 (90.6) 36 (6.8) 7 (1.3) 5 (0.9) 2 (0.4)
1960–1969 979 909 (92.8) 50 (5.1) 14 (1.4) 5 (0.5) 1 (0.1)
1970–1979 1,322 1,171 (88.6) 113 (8.5) 23 (1.7) 6 (0.5) 9 (0.7)
1980–1989 1,499 1,370 (91.4) 83 (5.5) 32 (2.1) 7 (0.5) 7 (0.5)
1990–1999 2,748 2,451 (89.2) 213 (7.8) 49 (1.8) 21 (0.8) 9 (0.3)
2000–2009 3,380 3,003 (88.8) 254 (7.5) 64 (1.9) 39 (1.2) 20 (0.6)
TOTAL 10,575 9,486 (89.7) 760 (7.2) 191 (1.8) 84 (0.8) 49 (0.5)
“ICC”-Invasive Cervical Cancer; “SCC”-Squamous Cell Carcinoma; “ADC”-Adenocarcinoma; “ADSCC”-Adenosquamous Cell Carcinoma; “OTHER”-Mostly un-
differentiated cases without NET cases; “NET”-Neuroendocrine Tumors; %: Row percentages.
(*) Five cases were excluded since histological diagnosis was performed in the centre of origin and slides were not retrieved to the reference lab for confirmation. The
total number of confirmed histological NET diagnosis were 49 out of 54 initially NET cases.
Table 2
Immunohistochemistry, electron microscopy results, p16INK4a overexpression and HPV DNA detection by neuroendocrine subtype histological classification.
Neuroendocrine markers HPV DNA detection and related markers
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11 (22.4) 0 4/11 8/11 6/10 3/10 2/2 11/11
(100.0)
10/11 (90.9) 7 (70.0) 2 (20.0) - 1 (10.0) -
Small cell
carcinoma














1 (2.4) 1 (2.4) HPV18&52
(1; 2.4)
"NET”-Neuroendocrine Tumors; "HPV"-Human Papillomavirus;"DNA"-Deoxyribonucleic Acid;"NA"-Not assessable/available for immunohistochemistry - IHC;
"Chrom"-Chromogranin; "Synap"-Synaptophysin;
* Immunohistochemistry markers negative (All 3 immunhistochemical markers performed and with a negative result);
** “EM NE+": Neuroendocrine differentiation on electron microscopy study (Only performed in cases with all available immunohistochemistry (IHC) markers
negative);
a) N=number of cases, %=percentage over total neuroendocrine tumors (NET); b) n=number of cases with a positive result for the specific immunohistochemistry
(IHC) marker, N=number of cases analyzed for the specific IHC marker, %: n/N; c) n=number of cases HPV positive, N=number of cases HPV analyzed, %: n/N; d)
HPV types %: number of cases positive for a specific HPV type among the HPV positive cases.
NOTE: p16INK4a was not performed in all cases, due to lack of tissue.
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4. Discussion
From a large international study of invasive cervical carcinoma, 49
NET were identified, which represents 0.5% of the total. This figure is
consistent with the low frequency (0.5–1%) previously reported in the
literature [1]. HPV DNA was detected in a vast majority of NET cases
(85.7%) confirming its role as in other cervical carcinoma histologies,
and reveals an almost equal contribution of HPV16 and HPV18 in its
etiology (HPV16 in 54.8% and HPV18 in 40.5%), while other HPV
types were rarely detected. In this series, HPV18 was four times
(40.5%) more frequent in NET than in the whole series of ICC (10.1%)
(p-value< 0.001). HPV type distribution in NET parallels what is found
in ADC and ADSCC. Previous data showed that 81.8% of the NET was
positive for HPV, with HPV18 detected in 73.1% and HPV16 in 30.8%
(Table 3) [5,12–28]. Percentage of HPV18 detection ranged from be-
tween 22% to 100%. This wide range can be due mainly to two causes.
The variability of the sample size on previous published data: more than
half of the papers were based on less than 20 cases. On the other hand,
LCC subtype can be easily confused with a poorly differentiated squa-
mous cell carcinoma based on the identification of focal areas of
squamous differentiation when no immunohistochemical markers are
used. This hypothesis is supported by the fact that most series include
mainly small cell neuroendocrine carcinomas and only few cases of
LCC. Grayson et al. [20] who also included LCC, detected 77.8% HPV16
and 22.2% HPV18. Therefore, probably in SmCC the contribution of
HPV18 is greater than in LCC.
The overall distribution of HPV types in cervical cancer has not
changed significantly over time. No time trend for SCC has been ob-
served; meanwhile in ADC has observed an increasing trend for HPV16
and a decreasing trend for HPV18 [30,31]. This may be due to a wider
coverage of cytology based screening programs allowing for detection
of concurrent lesions associated (i.e., joint detection of ADC and
squamous intraepithelial lesions, in large part HPV16 positive). In our
study, the number of NET detected cases is small and we cannot assess
any time trend. Broad series that include all subtypes of NETs are
needed to see if there has been any change over time.
A common occurrence of NET with premalignant or invasive
glandular cervical lesions has been reported [26,32,33] and neu-
roendocrine cells have been detected in normal endocervix [34] sug-
gesting that NET and ADC could have a similar origin or carcinogenic
pathway. The greater frequency of HPV18 in both NET and ADC ob-
served in our series and in other histologies (Table 3) is suggestive of
greater affinity of HPV18 for glandular and neuroendocrine cells as
compared to other HPV types. Indeed, in our study NET was more
frequently associated with concomitant glandular than with squamous
lesions.
Within NET, SmCC was the most frequent subtype identified
(67.3%), while 22.4% of the cases were LCC. The lower frequency of
LCC could be related to a more difficult differential diagnosis between
LCC and squamous cell carcinomas, poorly differentiated ADC or un-
differentiated carcinomas, taking into account that im-
munohistochemical neuroendocrine markers are not performed as a
routine staining [20,32–35]. The issue becomes relevant because under
the same clinical stage, prognosis is worse for NET than for SCC or ADC
of the cervix [5,6]. High clinical aggressiveness, frequent local re-
currences and distant metastases observed in NET [36,37] has been
demonstrated by a marked lymphatic permeation that occurs in these
tumors; a feature which is particularly characteristic of HPV18 related
tumors [27,37]. Unfortunately we could not evaluate the evolution of
our cases due to study design limitations, as no follow up data was
collected.
The diagnosis of NET is made primarily by the examination of
conventional HE sections. Immunostaining with chromogranin A, sy-
naptophysin and CD56 can help to establish the correct diagnosis
Fig. 3. Neuroendocrine differentiation evaluated by immunohistochemistry and electron microscopy. (a) Diffuse immunostaining for CD56 and (b) staining for
synaptophysin confirming the presence of neuroendocrine differentiation; (c) Diffuse staining for chromogranin; (d) Electron microscopic picture showing tumor cells
arranged concentrically in a rosette-like configuration, with a moderate amount of cytoplasm and round to ovoid nuclei, with a characteristic pattern of combined
euchromatin and heterochromatin, occasional small nucleoli and slight irregularities in the nuclear membrane outlines (Original magnification: 2600×); (e) Inset:
Detail of two cell processes containing numerous electron dense neuroendocrine granules, with diameters ranging from 71 nm to 181 nm. Primitive cell junctions can
be seen between them (Original magnification: 7900×).
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[26,37]. In our series, IHC markers of neuroendocrine differentiation
were detected in 65.8% of the tumors in which the three markers could
be performed. Albores Saavedra [38] and McCluggage [26] found CD56
to be the most sensitive marker of neuroendocrine differentiation
(61.5%) followed by chromogranin A (38.5%) and synaptophysin
(25.6%). In published series, immunoreactivity for chromogranin and
synaptophysin ranges from 50% to 100% [16,17]. The negativity of
these markers observed in our study could be attributed to differences
in the processing of tissue, some of them being very old, as 13 cases
were diagnosed before 1980 when buffered formalin was introduced in
pathology laboratories to optimize immunohistochemical staining. The
cases diagnosed before 1980 were more frequently negative (91.7%) in
Chromogranin marker than the cases diagnosed after 1980 (48.1%)
(Fisher's exacts p-value test< 0.02). However, most tumors that did not
show NET markers by IHC were SmCC, which harbor the most typical
histological features. In 6 SmCC with negative IHC markers, EM showed
neurosecretory granules. Therefore, by adding EM as a diagnostic tool
we reached a confirmation of neuroendocrine differentiation in 32 out
of 49 cases (65.3%). Immunohistochemistry can be very helpful in
confirming a diagnosis of NET but should not be used to disregard a
morphological diagnosis.
Diffuse and continuous, cytoplasmatic and nuclear, expression of
p16INK4a is an excellent immunochemical surrogate for SCC harboring
transforming high risk HPV due to HPV E7 mediated inactivation of
retinoblastoma tumor suppressor, and a negative feedback loop.
p16INK4a was found over-expressed in 86.4% of NET and showed good
concordance with the HPV result. In previous reports, 91–100%
[21,23,24] SmCC showed p16INK4a positivity while in this series it was
present in 78.6% of the cases. All of cases of atypical carcinoid and
large cell neuroendocrine carcinoma were positive for p16INK4a with a
similar proportion to that which is observed among SCC [10,11].
Another limitation of our study is the proportion of samples in
which HPV DNA was not detected, as this was observed in the overall
study [8]. The different procedures in transportation and fixation of the
samples among different laboratories may affect the rate of positive
HPV DNA detected; however since many centers from many different
countries were involved the analysis is not informative. No time trend
was detected which could explain the differences. If one accepts this
argument, all the cervical NET would be most likely HPV related tu-
mors.
This is a large series analyzed by PCR including all histological
neuroendocrine subtypes and the results confirm the role of HPV, in
particular HPV16 and 18. This fact is remarkable in the field of pre-
vention, since HPV vaccines currently available could prevent more
than 95% of these tumors.
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